Filing Flows

Filing Flows › Companies › TherapeuticsMD › Cash flow

TherapeuticsMD cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow$779K in Q2 2026 · $3.1M over twelve months

Operating cash flow$779K
Free cash flow+$779K
Cash / net income5.0×

Analysis

In Q2 2026, TherapeuticsMD generated $779K of operating cash flow. That is $398K more than in Q2 2025 ($381K).

Over the twelve months to Jun 30, 2026, operating cash flow was $3.1M; the cash balance rose by $3.1M.

Operating cash flow was $779K against net income of $155K — 5.0× profit, cash ran ahead of reported earnings. The largest differences: payables +$423K, accrued liabilities −$363K, depreciation & amortization +$95K.

Free cash flow

TherapeuticsMD: free cash flow by quarterTherapeuticsMD: free cash flow by quarter−$71KQ3 2024$17KQ4 2024$699KQ1 2025$381KQ2 2025$999KQ3 2025$375KQ4 2025$944KQ1 2026$779KQ2 2026
Operating cash flow less capital spending.
TherapeuticsMD: operating cash flow against capital spendingTherapeuticsMD: operating cash flow against capital spendingOperating cash flowCapital spending−$71K$0Q3 2024$17K$0Q4 2024$699K$0Q1 2025$381K$0Q2 2025$999K$0Q3 2025$375K$0Q4 2025$944K$0Q1 2026$779K$0Q2 2026
Latest (Q2 2026): Operating cash flow $779K, Capital spending $0.

Capital allocation, year by year

TherapeuticsMD: where the cash came from (up) and went (down), by fiscal yearTherapeuticsMD: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsFY2021: Operating cash flow −$143MFY2021: Net borrowing −$50.0MFY2021: Shares issued $184MFY2021: Capital spending −$34K$184MFY2021FY2022: Operating cash flow $9.4MFY2022: Net borrowing −$219MFY2022: Shares issued $24.1M$33.5MFY2022FY2023: Operating cash flow −$23.1MFY2023: Shares issued $3.2MFY2023: Acquisitions −$140M$3.2MFY2023FY2024: Operating cash flow $1.2MFY2024: Acquisitions −$140M$1.2MFY2024FY2025: Operating cash flow $2.5MFY2025: Acquisitions −$140M$2.5MFY2025
Over these 5 years operating cash flow totalled −$153M; the largest uses were acquisitions ($420M) and net borrowing ($269M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$9.2M
Debtnone
Net cash$9.2M

TherapeuticsMD funds itself: free cash flow was $3.1M over the last twelve months, with $9.2M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

TherapeuticsMD: sources (+) and uses (−) of cash, Q2 2026TherapeuticsMD: sources (+) and uses (−) of cash, Q2 2026Operating cash flow$779KCash drawn (+) / kept (−)−$770KNot reconciled−$9K
TherapeuticsMD: sources (+) and uses (−) of cash, TTM to Q2 2026TherapeuticsMD: sources (+) and uses (−) of cash, TTM to Q2 2026Cash drawn (+) / kept (−)−$3.1MOperating cash flow$3.1MNot reconciled$23K

From profit to cash

TherapeuticsMD: net income to operating cash flow, Q2 2026TherapeuticsMD: net income to operating cash flow, Q2 2026Net income$155KDepreciation & amortization$95KStock-based pay$4KPayables$423KAccrued liabilities−$363KPrepaid and other assets$95KOperating cash flow$779K
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCash drawn (+) / kept (−)Free cash flow
Q2 2026$779K−$770K$779K
Q1 2026$944K−$936K$944K
Q4 2025$375K−$368K$375K
Q3 2025$999K−$1.0M$999K
Q2 2025$381K−$324K$381K
Q1 2025$699K−$686K$699K
Q4 2024$17K−$12K$17K
Q3 2024−$71K$185K−$71K

TherapeuticsMD: income statement and cash flow

TherapeuticsMD, Q2 2026: revenue $869K (-9% year over year), operating margin -93.9%. The chart follows the revenue to costs, profit and cash.

TherapeuticsMD: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.